Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension StudyOriginal Research Published on 2024-04-042024-09-05 Journal: Advances in therapy [Category] update2024, [키워드] clinical trial Complement inhibitor eculizumab FACIT-Fatigue hemoglobin Open-label extension paroxysmal nocturnal hemoglobinuria (PNH) pegcetacoplan thrombosis transfusion [DOI] 10.1007/s12325-024-02827-8 PMC 바로가기 [Article Type] Original Research
Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III studyarticle Published on 2023-09-182024-09-02 Journal: Arthritis Research & Therapy [Category] 대상포진, [키워드] ankylosing spondylitis biologic Inadequate response Janus kinase inhibitor Open-label extension refractory tumor necrosis factor Upadacitinib [DOI] 10.1186/s13075-023-03128-1 PMC 바로가기 [Article Type] article
Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn’s Disease: Results from the Phase 2 Open-Label Extension StudyOriginal Article Published on 2021-12-022024-09-04 Journal: Journal of Crohn's and Colitis [Category] 대상포진, [키워드] Crohn’s disease long-term safety Open-label extension [DOI] 10.1093/ecco-jcc/jjab093 PMC 바로가기 [Article Type] Original Article